This phase I trial is testing a new drug (CEND-1) in combination with chemotherapy (Nabpaclitaxel and Gemcitabine) in patients with exocrine pancreatic cancers that have spread to other parts of the body.
This trial is treating patients with exocrine pancreatic cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic Cancer
This trial involves a does escalation and expansion phase. In the dose escalation phase, participants will receive three different CEND-1 dose levels, first as a monotherapy and followed by combination therapy with nabpaclitaxel and gemcitabine. In the dose expansion phase, approximately 28 subjects will receive combination treatment with two different CEND-1 dose levels.
Recruiting Hospitals Read More